ELECTROPHYSIOLOGY

PACE willey

Comparison between same-day discharge and overnight stay after atrial fibrillation ablation: Systematic review and meta-analysis

Narut Prasitlumkum MD¹ Visit Cheungpasitporn MD² Ronpichai Chokesuwattanaskul MD^{3,4,5} IJakrin Kewcharoen MD⁶ I Nithi Tokavanich MD^{3,5} Leenhapong Navaravong MD⁷ Krit Jongnarangsin MD⁸

¹ Division of Cardiology, University of California Riverside, Riverside, California, USA

² Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

³ Division of Cardiovascular Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand

⁴ Cardiac Center, King Chulalongkorn Memorial Hospital, Bangkok, Thailand

⁵ Center of Excellence in Arrhythmia Research Chulalongkorn University, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

⁶ Department of Cardiology, Loma Linda University, Loma Linda, California

⁷ Division of Cardiovascular Medicine, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah, USA

⁸ Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA

Correspondence

Narut Prasitlumkum, MD, University of California Riverside, 900 University Ave, Riverside, CA 92521, USA. Email: narutprasitlumkum@gmail.com

Abstract

Background: In the modern era, atrial fibrillation (AF) ablation trend has been shifted toward same-day discharge (SDD), from a traditional overnight stay. Yet, recent studies have not well stated the safety profiles which remained poor-understood and dispersed. We hence performed systematic review and meta-analysis to assess the adverse outcomes of SDD in comparison with an overnight stay.

Methods: Databases were searched through January 2021. Effect estimates from the individual studies were extracted and combined using random-effects, generic inverse variance method of der Simonian and Laird. The primary outcomes included total cumulative complications and immediate complications following AF ablation.

Results: Ten observational studies were met our inclusion criteria, comprising of total population of 11,660 patients, with SDD 51.3%. For total cumulative complications, there were no differences observed between SDD and overnight stay (5.2% vs. 6.2%: pooled OR 0.77: 95% CI 0.55–1.08, p = .13 with $l^2 = 27.1\%$). In addition, comparable immediate complications were also demonstrated (5.2 % vs. 4.3: pooled OR 1.08: 95% CI 0.72–1.62, p = .718, with $l^2 = 37.3\%$).

Conclusion: Our study suggested that SDD had similar complication rates, both total cumulative and immediate outcomes, compared with overnight stay in selected patients following AF ablation. Nevertheless, randomized control trials are warranted to validate the findings.

KEYWORDS

atrial fibrillation ablation, overnight stay, same day discharge

Abbreviation: AF, atrial fibrillation; COVID-19, coronavirus disease2019; GA, general anesthesia; ICE, intracardiac echocardiogram; RCT, randomized control trial; RFA, radiofrequency ablation; SDD, same-day discharge; TEE, transesophageal echocardiogram; TIA, transient ischemic attack; UK, United Kingdom.

1 | INTRODUCTION

In the past decades, a trend toward AF ablation has been significantly rising, reflecting a higher fidelity in this technology.¹ Despite the promising clinical advantageous demonstrated by previous studies,^{2–4} higher rates of hospitalization for the procedure have been observed, accompanied by a significant increment in medical cost for hospital stay up to 60%.⁵ As an estimated AF prevalence and incidence across all age groups are projected toward 60% worldwide in 2050,⁶ the needs of AF treatment, including AF ablation, are subjected to proportionally increasing.

Recently, same-day discharge (SDD) protocol is recommended for elective percutaneous coronary intervention (PCI) if certain criteria are met.⁷ This is in response to the emerging of COVID-19, which requires extensive resources and healthcare utilization.⁸ With current greater understanding and experience in AF ablation, an outpatient setting for the catheter ablation sounds conducive, feasibly resorting and allaying the impacts of this world great pandemic. Previous studies have suggested potential merits of using SDD protocol, providing medical efficiency while reducing medical expenses.^{9,10} Nevertheless, there remains uncertainty in employing this strategy given the lack of standardized protocol and limited data on clinical outcomes.

We hence conducted this comprehensive systematic review and meta-analysis of all relevant data to determine the safety profiles between SDD and overnight stay following AF ablation.

2 | METHODS

2.1 | Protocol registration

This study was compiled with MOOSE¹¹ (Meta-analysis of Observational Studies in Epidemiology) statement as described in online supplementary data. The protocol was also registered with PROS-PERO (International Prospective Register of Systematic Reviews; -CRD42021231537). Institutional review board approval was not sought because of the use of publicly available cumulative published data.

2.2 | Literature review and search strategy

A systematic literature search of MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews was conducted, retrieving databases from inception to January 2021. Search terms were included "same day discharge", "day care", "day case", "short stay", "catheter ablation" and "atrial fibrillation", provided in online supplementary data 1.

2.3 | Study selection

Citations were stored, and duplicates were removed using the End-Note software (Thomson Reuters, Toronto, Ontario, Canada). Two independent reviewers (Narut Prasitlumkum and Ronpichai Chokesuwattanaskul) screened the abstracts and titles of the studies and subsequently reviewed the full-text articles for inclusion on the Rayyan ([http://rayyan.qcri.org] a free web-based and mobile articles screening tool which was designed to screen titles/abstracts for the relevant search terms through academic search engines).¹² No language restriction was limited. A manual search for conceivably relevant studies using references of the included articles was also performed. Authors of the included trials were contacted to clarify unclear information, if necessary. When there were disagreements between the reviewers, we have discussed until we reach a consensus. Newcastle-Ottawa quality assessment scale (NOS) was used to appraise the quality of study for case-control study and outcome of interest for cohort study, as shown in supplementary 3.¹³

2.4 | Inclusion criteria

- 1. Study type: Cross-sectional, case-control, cohort studies, or RCT
- 2. Patient population: Adults > 18 years old undergoing AF ablation
- 3. Intervention: Discharge on the same day after AF ablation
- 4. Control: Overnight stay after AF ablation and discharge based on clinician's discretion
- 5. Outcomes: Total complications

2.5 | Data extraction and outcome

Comprehensive data extraction was performed to derive the following information from each study, including title, year of the study, name of the first author, publication year, country where the study was conducted, demographic and characteristic data of subjects, total numbers of participants in each study and discharge protocol (SDD, overnight stay) and total complications. For the most accurate analysis, we utilized OR/RR/HR from multivariable adjustment from studies that contain content of the available data. Otherwise, we extracted absolute numbers provided in each cohort and proceeded with univariate analysis.

First primary outcome: Total complications. It was defined by a summation of any cardiac and noncardiac procedural-related events till the end of follow-up, in which each study was defined, ranging from 30 to 180 days after patients were discharged.

Second primary outcome: Immediate complications. It was defined by a summation of any cardiac and noncardiac procedural-related events within 48 h.

Secondary outcome: Total bleeding events, total pericardial conditions, total stroke/TIA, and total phrenic nerve injury.

Exploratory outcomes: In a *post hoc* manner, our decision was made to investigate which factors were associated with successful SDD. Factors included in this study were retrieved directly from reported studies. Not limited to this notice, other potential factors were considered in line with authors' agreement after reviewing inherent studies which described predictors of complications following AF ablation.¹⁴⁻¹⁸ This

WILEV

consensus was constituted based on the assumption that postprocedural complications prevent successful early discharge.

2.6 | Outcome ascertainment

For immediate complications detection, routine postprocedural surveillance was performed according to each study's protocol. Routine postprocedural physical exam was performed by medical providers. All readmission and ER visits medical records were reviewed.

For other complications detection, patients were routinely followed up at the clinics of participating centers in each study. Routine physical exam was performed by medical providers and all relevant medical records, including outpatient follow-up, ER visits, and hospital readmission after the procedure within follow-up periods according to each study.

2.7 | Statistical analysis

Random-effects model was used to perform meta-analysis given anticipated between-study heterogeneity. Standardized mean differences (SMDs) were used to estimate effect sizes for continuous data. To dichotomize continuous data, if necessary, Hasselblad and Hedges' method was used for conversion, assuming near-normal logistic distribution and equal variance.^{19,20} For dichotomous data, generic inverse variance method of der Simonian and Laird²¹ was used to estimate odds ratios (ORs) and 95% Cls. The heterogeneity of effect size estimates across studies was quantified using the Mantel-Haenszel chisquare test and I² statistics. Substantial heterogeneity was predefined as p < .10 for Mantel-Haenszel chi-square test. The I² statistic ranges in value from 0% to 100% (I² < 25%, low heterogeneity; I² = 25% to 50%, moderate heterogeneity; and I² > 50%, substantial heterogeneity).¹³

In accordance with Cochrane, publication bias was assessed by evaluation of the symmetry of a funnel plot. Egger's linear regression test and Begg's rank correlation test were used for objective evaluation, of which the presence of publication bias is defined by p < .05. All analysis was performed using STATA version 16 (College Station, TX, USA: StataCorp LLC).

3 | RESULTS

A total of 475 potentially eligible articles were identified through Rayyan¹² using our search strategy. One hundred and fifteen articles were excluded due to duplicated studies. After the exclusion of 217 articles as the inclusion criteria were not fulfilled, there were 28 articles left for full-length review. Fifteen were excluded as no SDD protocol was implemented. One was excluded because patients undergoing AF ablation were excluded. One was excluded as it was only an editorial comment. Lastly, one study was excluded substantial patients who lost follow-up during the study timeframe. Thus, the final analysis

included 10 observational studies (seven retrospective cohort studies, three prospective cohort studies).²²⁻³¹ The literature retrieval, review, and selection process are demonstrated in Figure 1. The characteristics and quality assessment of the included studies are presented in Table 1. Selection criteria and definitions of complications from each study were summarized in Table 2.

3.1 Study characteristics and quality assessment

Total populations included in our study were 11,660 (51.3% under SDD protocol and 48.7 under overnight stay). 60.5% of included studies' populations were female, with an average age of 61.7 \pm 9.7 years old. Mean follow-up time was 54 days (range 30–180 days). The proportion of echocardiography-guided catheter ablation usage (ICE/TEE) was extensively varied, from 0% to 100%. Postprocedural echocardiography was routinely employed in the majority of included studies^{22,23,27-29} except Akula et al.³⁰ as ICE was already used periprocedurally. For Bartoletti et al., Reddy et al., and Deyell et al.,^{24–26} echocardiogram was performed only if clinically indicated. It was not clearly specified in Ignacio et al. whether routine echocardiogram was used.

In SDD group, only 2.5% (148/5981) was not discharged on the same day as planned. Up to 42.5% (63/148), the reason for prolonging admission was inherently due to procedural-related complications. On the other hand, the rest was not relevant to the procedure, including patient's preference, late procedures, and patient's non-procedural medical problems.

Majority of anticoagulation methods were uninterrupted plans. RFA was the main ablation type commonly used (58.8%) in our meta-analysis. Overall mortality rates in this cohort are extremely low (< 0.01%) in both SDD and overnight stay. NOS has ranged from 6 to 8, indicating moderate to high qualities of included studies.

3.2 | Primary outcome

For total cumulative complications rates, there was no difference between SDD (5.2%) and overnight stay (6.2%) (pooled OR 0.77: 95% Cl 0.55–1.08, p = .13). There was moderate heterogeneity in this analysis (I² = 27.1%). Similarly, no statistical differences in immediate complications were observed in both protocols (5.2 % in SDD vs. 4.3 % in overnight stay; pooled OR 1.08: 95% Cl 0.72–1.62, p = .718, with moderate heterogeneity (I² = 37.3%) (Figure 2).

3.3 Secondary outcome

Common complications including total bleeding events, total pericardial complications, total stroke/TIA and total phrenic nerve injuries were individually sought. No differences were found between SDD and overnight stay in total bleeding (1.4 % vs. 2.6 %; pooled OR 1.25: 95% CI 0.62–2.51, p = .528), stroke/TIA (0.24 % vs. 0.17 %; pooled OR 1.25:

PRASI	TLUMKUM	ET AL.																-V	VILEY $^{\perp}$	2
	coagulation egy	ators' eferences		terrupted irfarin and nimally errupted DACs		terrupted ticoagulation		d (majority is errupted plan)	terrupted ticoagulation		ators' eferences		rupted ticoagulation		terrupted ticoagulation		terrupted ticoagulation		terrupted irfarin and nimally bACs	(Continues)
	Anti strat	Opei pr		Unir w D		Unir an		Mixe int	Unir an		Opei		Inter an		Unir an		Unir an		Cuir D in m	
	Follow up duration (days)	90 days		90 days		30 days		30 days	120 days		30 days		30 days		90 days		90 days		180 days	
	Male (%)	60	52	68.5	68.1	60.1	68.2	73.8	43	45	67	69	75.2	84.5	60	61	61	61	72.9	
	Mean age (Years old)	60.2	62.3	59±11	59 ± 11	62.9 ± 11.3	61.1 ± 12.5	60.4 ±9.5	59.7±12.1	62.5 ± 10.8	66 ± 10	64 ± 11	57.3 ± 12.9	59.9 ± 10.5	60±0.8	61 ± 0.7	59.9 ± 12.8	58.5 ± 9.9	60.36±10.0	
	al population	145	426	642	143	1901	727	3054	553	414	1180	1194	137	58	276	276	41	41	168	
	Tot	NO	SDD	NO	SDD	NO	SDD	All	NO	SDD	NO	SDD	NO	SDD	NO	SDD	NO	SDD	ZO	
tudies	Total numbers of centers	Single		Single		Multicenter		Multicenter	Multicenter		Multicenter		Single		Multicenter		Single		Single	
cs of included st	Country	USA		Х		NK		Canada	Ч		USA		Argentina		Х		USA		ž	
udy characteristi	Study type	Retrospective cohort		Retrospective cohort		Retrospective cohort		Retrospective cohort	Retrospective cohort		Retrospective cohort		Prospective cohort		Prospective cohort		Prospective cohort		Retrospective cohort	
TABLE 1 Sti	Study (year)	Akula 2020		Bartoletti 2019		Creta 2020		Deyell 2020	He 2020		Kowalski 2020		Mondrago 2018		Opel 2019		Rajendra 2020		Reddy 2020	

(Continued)	
-	
щ	
Ы	
₹	

on Verare of (100^{10}) (30) duration (lasted) fit all sign $0.142^{+}9$ 7.08 1.08 1.01 1.01 $0.142^{+}9$ 1.08 1.01 1.01 1.01 $0.142^{+}9$ 1.08 1.01 1.01 1.01 $0.142^{+}9$ 1.01 1.01 1.01 1.01 $0.014^{-}0.01$ 0.01 0.01 0.01 0.01 $0.010^{-}0.01$ $0.02^{-}0.01$ $0.02^{-}0.00000000000000000000000000000000000$				Total numbers of		:	Mean age	Male	Follow up	Anticoagulation			
Interface Conditients Unditients PhorAF BM ablation ablation BM 1 NorAF BM 1 ablation BM 1 bM 1 <td< th=""><th>Study type Country centers Total p</th><th>Country centers Total p</th><th>centers Total p</th><th>Total p</th><th>D</th><th>opulation</th><th>(Years old)</th><th>(%) 20 o</th><th>duration (days)</th><th>strategy</th><th></th><th></th></td<>	Study type Country centers Total p	Country centers Total p	centers Total p	Total p	D	opulation	(Years old)	(%) 20 o	duration (days)	strategy			
Hypertension Hypertension Cardiomyopathy Properting Propering	General Use of Ablation strategy Pro anesthesia ICE/TEE (%) guidance	Use of Ablation strategy Pro ICE/TEE th guidance	Ablationstrategy Pro	titategy Pro	Pro	cedural ime (min)	Prior AF ablation (%)	BMI		Comorbi	idities		
n/a n/a <th>Cryo RFA (%) (%)</th> <th>Cryo RFA (%) (%)</th> <th>Cryo RFA (%) (%)</th> <th>Cryo (%)</th> <th></th> <th></th> <th></th> <th></th> <th>Hypertension (%)</th> <th>DM2 (%)</th> <th>Cardiomyopathy (%)</th> <th>prior Stroke/TIA (%)</th>	Cryo RFA (%) (%)	Cryo RFA (%) (%)	Cryo RFA (%) (%)	Cryo (%)					Hypertension (%)	DM2 (%)	Cardiomyopathy (%)	prior Stroke/TIA (%)	
nia nia nia nia nia nia ±43 206 23.5 ± nia nia nia nia ±43 206 29.5 ± nia nia nia nia ±29 40.6 29.4 ± bia nia nia nia ±83 40.4 nia nia nia nia nia ±69.7 nia nia nia nia 132 nia ±69.7 nia nia nia nia 132 nia ±69.7 nia nia nia 132 nia 13 ±71.8 15 nia nia 132 nia 13 ±74.0 13	n/a 100% (ICE) 100 0 n/	100 % (ICE) 100 0 n	100 0 n/	л 0	È	e,	n/a	n/a	n/a	n/a	n/a	n/a	
±43 20.6 29.5± i/a i/a i/a i/a ±29 40.6 5.2 0/3 0/3 0/3 0/3 ±29 40.6 29.4± 0/a 0/a 0/a 0/a ±83 40.4 n/a n/a n/a 15.0 n/a 1/a ±83 40.4 n/a n/a n/a 10.90 n/a 1/a ±83 138 n/a 1/a 1/a 1/a 1/a 1/a ±69.7 n/a 1/a 1/a 1/a 1/a 1/a ±14.8 1/a 1/a 1/a 1/a 1/a<	Ĉ.	È.	ſĽ	Ĺ	È	e,	n/a	n/a	n/a	n/a	n/a	n/a	
± 29 406 294± ind ind ind ind ind ± 83 40.4 ind ind ind ind ind ind ind ± 83 40.4 ind ind ind ind ind ind ind ± 83 40.4 ind ind ind ind ind ind ± 138 ind ind ind ind ind ind ind ± 93 ind ind ind ind ind ind ind ± 93 ind ind ind ind ind ind ind ± 93 ind ind ind ind ind ind ind ± 93 ind ind ind ind ind ind ind ± 93 ind ind ind ind ind ind ind ± 10 ind ind ind ind	46.2 Not 67.6 32.4 15 mentioned	Not 67.6 32.4 15 mentioned	67.6 32.4 15	32.4 15	15	3 ± 43	20.6	29.5 ± 5.2	n/a	n/a	n/a	n/a	
± 83 40.4 n/a n/a n/a 15.50 n/a 42 13.8 n/a n/a 10.90 n/a 42 13.8 n/a n/a 10.90 n/a 43 13.8 n/a 39.9 8 13.2 7.8 49.7 n/a 39.9 8 13.2 7.8 49.7 n/a 10 13.2 7.8 2±718 15 n/a 13.2 7.8 2±718 15 n/a 13.2 7.8 2±718 15 n/a 13.2 7.8 2±718 15 16 16 16 2±80.7 71 16 16 16 2±80.7 73 18 10 5	62.5 61.5 38.5 12	61.5 38.5 12	61.5 38.5 12	38.5 12	12	0±29	40.6	29.4± 5.0	n/a	n/a	n/a	n/a	
42 13.8 π/a π/a <th a<="" t<="" td="" π=""><td>8.4 30.6% (Only 62.6 37.4 150. ICE, no TEE use in this study)</td><td>30.6 % (Only 62.6 37.4 150. ICE, no TEE use in this study)</td><td>62.6 37.4 150.</td><td>37.4 150.</td><td>150.</td><td>± 83</td><td>40.4</td><td>n/a</td><td>n/a</td><td>n/a</td><td>15.50</td><td>n/a</td></th>	<td>8.4 30.6% (Only 62.6 37.4 150. ICE, no TEE use in this study)</td> <td>30.6 % (Only 62.6 37.4 150. ICE, no TEE use in this study)</td> <td>62.6 37.4 150.</td> <td>37.4 150.</td> <td>150.</td> <td>± 83</td> <td>40.4</td> <td>n/a</td> <td>n/a</td> <td>n/a</td> <td>15.50</td> <td>n/a</td>	8.4 30.6% (Only 62.6 37.4 150. ICE, no TEE use in this study)	30.6 % (Only 62.6 37.4 150. ICE, no TEE use in this study)	62.6 37.4 150.	37.4 150.	150.	± 83	40.4	n/a	n/a	n/a	15.50	n/a
$\epsilon 69.7$ n/a 39.9 8 13.2 7.8 2 ± 71.8 15 n/a n/a n/a n/a 2 ± 71.8 15 n/a n/a n/a n/a 2 ± 71.8 15 n/a n/a n/a n/a 2 ± 80.9 7.7 n/a n/a n/a n/a 2 ± 80.9 7.7 n/a 31 ± 6 72 21 16 6 30 ± 6 72 18 10 5 $1/a$	34.8 20.8 79.2 79 ₋₁	20.8 79.4	20.8 79.2 79 ₋₁	79.2 79 _±	79 _±	± 42	13.8	n/a	n/a	n/a	10.90	n/a	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	98.7 53.5% 96.5 3.5 19((TEE)0.3 % (ICE)	53.5% 96.5 3.5 19((TEE)0.3 % (ICE)	96.5 3.5 19(3.5 190	190)±69.7	n/a	n/a	39.9	ω	13.2	7.8	
2 \pm 80.9 7.7 n/a n/a n/a n/a 5 n/a n/a n/a $31\pm$ 6 72 21 16 6 $31\pm$ 6 73 $30\pm$ 6 72 18 10 5	6 Not 92.1 6.9 16 mentioned	Not 92.1 6.9 166 mentioned	92.1 6.9 169	6.9 169	169	<i>9</i> .2± 71.8	15	n/a	n/a	n/a	7	n/a	
n/a 31 ± 6 72 21 16 6 30 ± 6 72 18 10 5	2 21.3 78.7 146.	21.3 78.7 146	21.3 78.7 146.	78.7 146.	146.	2± 80.9	7.7	n/a	n/a	n/a	5	n/a	
30 ± 6 72 18 10 5	100 100%(ICE) 0 100 n/a	100%(ICE) 0 100 n/a	0 100 n/a	100 n/a	n/a		n/a	31 ± 6	72	21	16	6	
								30 ± 6	72	18	10	5	

²⁰⁵⁸ WILEY-

rior troke/TIA %)	/a					6.	/a		available; ON
pathy S (9	c			4	0	4	C		am; n/a, not
Cardiomyo (%)	n/a		n/a		0	4.9	n/a		ac echocardiogi s of America.
M2 (%)					4		a		; ICE, intracardi SA, United State
sion D	17	9	6	7	2.4		lu Na		llitus type 2 Kingdom; U
Hyperten (%)	59	24	61	47	56.1		n/a		diabetes me UK, United
	27.7± 4.5	28.4± 3.8	n/a	n/a	29.7± 4.6	30.1± 5.2	n/a	n/a	lants; DM2, emic attack;
	9.6	0			6	e	3.6		ral anticoagu ransient isch
	19	20	0	6	4	7.5	28	22	, direct or am; TIA, t
	n/a		63.5± 1.1	101.7 ± 2	67±22	59 ± 15	160.76 ± 48.6	139.66 ± 37.8	tion; DOACs chocardiogr
Cryo (%)	n/a		100		0		22.9	42.9	oballoon abla esophageal e
FA (%)	e,				00		3.6	7.1	x; Cryo, cryc e; TEE, trans
2	n, ned		se er		10 ined		ned 7.	in	mass inde discharg
	Not mentio		0% (No ur of eithe TEE or ICE)		Not mentio		Not mentio		BMI, body D, same-day
									l fibrillation; squency; SD
	100		89		100		60.1	29.2	: AF, atria radiofre
	Mondrago 2018		Opel 2019		Rajendra 2020		Reddy 2020		Abbreviations: overnight; RFA

TABLE 1 (Continued)

.

2060)	WILE	Y							PRA	SITLUMKUM ET /
	Definition of complications	Death, pericardial tamponade, CVA, hematoma requiring PV stenosis, diaphragmatic paralysis or atrioesophageal fistula formation	Not defined	Death, cardiac tamponade, stroke or TIA, major vascular complications, bradyarrhythmia, persistent PN palsy, air embolus, esophageal fistula, gastroparesis, pharyngeal perforation	Access site complication, pericardial effusion, CVA, PN palsy	Hypotension requiring support, acute pulmonary edema, pericardial effusion/pericardial tamponade stroke, vascular injury/bleedingPN palsy, AV node injury	Death, pericardial effusion, TIA, HF, hematoma, PN palsy, pericarditis	pericardial effusion requiring intervention, vascular complications, hematoma, PN injury	Pericardial effusion or cardiac tamponade, pericarditis, bradycardia, vascular injury, PN injury, air embolus	Complications involving groin, respiratory, cardiac, or bleeding	Death, cardiac tamponade, CVA, vascular complications, bradyarrhythmia, PN palsy, air embolus, pulmonary edema, leg numbness, migraine
	SDD protocol	Patients were monitored for at least 6 h post ablation and were reassessed by the nursing staff prior to discharge including inspection of groin access sites. SDD was cancelled if patient had any ablation related complications, non-ablation related medical care or due to patient specific/social reasons.	Patients remained on bed rest for 4 h and were subsequently mobilized in the presence of nursing staff; any bleeding from the femoral access site mandated another hour of bed rest before subsequent mobilization. After, patients were offered the choice of either staying overnight or going home in the absence of severe left ventricular dysfunction or a recent history of uncontrolled HF.	Referring physicians identified patients who would not be suitable for SDD prior to the procedure. Patients were monitored for at least 4 h post ablation. In the absence of clinical concerns, suitable patients were discharged by the nurse with no physician review on the same day using a pre-specified workflow, including evaluation of the femoral access site, observations, national early warning score, electrocardiogram, and symptoms.	Patients were monitored for up to 8 h. Patients were discharged if ambulation was well tolerated with no access site bleeding and vital signs were stable	Not reported	Patients were discharge on the same day if was cleared by the operator after the procedure based on clinical standards-of-care at each hospital with most patients with an intraprocedural complication not eligible for SDD.	Not reported	Patients were monitored for 4 h and were discharged if cleared by nurse.	Prior to procedure, patients needed to be on stable anticoagulation with no bleeding history, acceptable CHA2DS2-VASc stroke risk, BMI < 35, and without systolic HF, respiratory conditions, or interventional procedures within 60 days. After the procedure, patient can be discharged home if patients were hemodynamically stable, in the absence of any complications including groin or respiratory complications, able to ambulate and tolerate liquids/food. Confirmation needed to be made by operator to proceed with SDD.	Patients were monitored on bed rest for 2 h. If groin haemostasis was acceptable and patients were clinically stable after this 2-h period they could be gently mobilised. If after a further 1-h observation, there were no evident complications anticoagulation could recommence and the patient could be discharged.
	lotal participants	571	785	2,628	3,054	967	2,374	195	276	82	448
	First author, year	Akula, 2020	Bartoletti, 2019	Creta, 2020	Deyell, 2020	He, 2020	Kowalski, 2020	Mondrago Ignacio, 2018	Opel, 2019	Rajendra, 2020	Reddy, 2020

AV, atrioventricular; BMI, body mass index; CVA, cerebrovascular accident; HF, heart failure; PN, phrenic nerve; PV, pulmonary vein; SDD, same-day discharge, TIA, transient ischemic attack.

 TABLE 2
 Summary of selection criteria for SDD of included studies, and definitions of complications





FIGURE 1 PRISMA flow diagram [Color figure can be viewed at wileyonlinelibrary.com]

95% CI 0.41–3.73, p = .709), pericardial complications (0.8% vs. 1.9%; pooled OR 0.64: 95% CI 0.20–1.98, p = .433) and phrenic nerve injuries (0.6% vs. 0.4%; pooled OR 1.26: 95% CI 0.24–6.64, p = .783) (Figure 3a and 3b).

3.4 | Exploratory analysis

Factors associated with increased likelihood of discharge on the same day were male gender (pooled OR 1.31: 95% CI 1.11–1.56, p = .002), use of conscious sedation (pooled OR 0.26: 95% CI 0.16–0.45, p < .001), and shorter procedural duration (pooled SMD–3.06 95% CI –4.12–2.00, p < .001). Age (pooled SMD–0.01: 95% CI –0.14–0.12, p = .870), hypertension (pooled OR 0.93: 95% CI 0.59–1.48, p = .769), previous ablation (pooled OR 0.93: 95% CI 0.51–1.69, p = 0.807), diabetes (pooled OR 1.07: 95% CI 0.89–1.29, p = .466), cardiomyopathy (pooled

OR 0.84: 95% CI 0.51–1.38, p = .490), use of cryoablation (pooled OR 1.80: 95% CI 0.58–5.62, p = .309) and prior stroke (pooled OR 0.77: 95% CI 0.47–1.25, p = .288) were not associated with higher SDD rates.

3.4.1 | Publication bias

Publication bias was not found from funnel plots, Beggs' rank correlation, and Egger's linear regression test for both first and second primary outcomes (Supplementary file).

4 DISCUSSION

Our systematic review and meta-analysis demonstrated that the SDD protocol for patients undergoing AF ablation was not associated with



FIGURE 2 Forest plot of the included studies comparing total and immediate complications rates between SDD and overnight stay [Color figure can be viewed at wileyonlinelibrary.com]

higher immediate or total procedural complications than an overnight stay. The incidence rates of common complications, including bleeding, pericardial events, stroke/TIA, phrenic nerve injury, and death, were not significantly different in both groups. Moderate heterogeneity was observed given between-study differences, which was anticipated due to varieties in studies' protocols and methodologies. Of note, the exploratory analyses suggested that male gender, use of conscious sedation, shorter procedural duration were associated with successful discharge on the same day after AF ablation.

Overnight observation is a common practice after AF ablation due to the complexity of the procedure and the need of anticoagulation. Although this convention is reasonable, SDD after AF ablation may render better cost-effectiveness in-hospital resource utilization, especially in the era of COVID-19 pandemic. Recent studies from the UK highlighted considerable annual cost-savings, approximately 98 k to 126 k\$, in implementing the SDD protocol compared with an overnight stay.²²⁻²⁴ In our opinion, SDD plan for patients undergoing AF ablation does not only help minimize hospital stays and preserve available beds for sicker patients affected by the current worldwide COVID-19 outbreaks, but also provides an efficient and cost-reduced framework in the future.

Our study showed that total complication rates were not different in both primary and secondary outcomes between SDD and an overnight stay. Total complication rates from our analysis ranged from 3% to 5%, which were slightly lower than the previous reports.^{32,33} The incidence of common complications in our study, especially bleeding events, was reported as low as 1.5%-2%. Similarly, the incidence rates of pericardial complication, stroke/TIA, and phrenic nerve injury were extremely low, significantly less than 1%, consistent with recent studies.^{33,34} Moreover, mortality rate in our study was found extremely uncommon, < 0.01%. These findings may stem from tremendous improvement in catheter and three-dimensional mapping technologies, allowing shorter procedural times and fewer complications.^{35,36} Use of echocardiography guided catheter ablation, both TEE and ICE, is another crucial factor that plays a significant role in facilitating shorter procedural duration, fluoroscopy time and doses, as well as fewer complications.^{37,38} Direct visualization of cardiac anatomy in several stages during the procedure, especially transeptal puncture, ensures

WILEY



FIGURE 3a Forest plot of the included studies comparing bleeding complications and Strok/TIA between SDD and overnight stay [Color figure can be viewed at wileyonlinelibrary.com]

certain positions, mitigating risks of ruptures, tamponade, and pulmonary vein stenosis. The uninterrupted anticoagulation, as well as better postprocedural care, are also considered as one of the main contributions in these findings. Overall, the safety profile of SDD protocol is favorable, readily to be more implemented in clinical practices.

Considering SDD protocols from each study, similar strategies have been adopted, essentially in patients with stable hemodynamic status and the ability to ambulate post-procedurally. Some studies required proximity of patients' residential areas within designated ranges from hospitals as well as great social supports. Nevertheless, the decision whether patients were discharged or stayed overnight mostly derived from operators' discretion, owing to the absence of standardized guidelines for SDD plans. In our exploratory analysis, it is suggested that male gender, shorter procedural time, and conscious anesthesia are factors favoring SDD. Several studies reported substantially higher complication rates among females compared with males.^{33,39,40} We speculate that gender-related anatomical differences, such as smaller heart and vascular structures, as well as smaller body sizes, in females compared with males, may impact the procedures difficulty.^{41,42} Catheter manipulation under the limited spaces may theoretically predispose the higher complication risks. For this reason, a longer observation in females is anticipated after AF ablation procedure, as observed in our exploratory analysis. Also, the shorter procedural time and conscious anesthesia may expedite patients' recovery in periprocedural phases and lead to early discharge, especially prior to afternoon time in some studies' protocols.^{25,29}

4.1 | Strength and limitation

Strengths of our study are as follows. First, this is the first and most comprehensive, and largest systematic review and meta-analysis to provide the current understanding in terms of safety profiles on SDD protocol in comparison with overnight stay. Second, from our pool database, we investigated with our best to explore if any clinical factors could favor successful SDD. Despite the hypothesis-generating context, we believe this information is useful in determining potential candidates for SDD. Third, the generalizability of our analysis well suffices,

WILEY

Study, year OR (95% CI) % Weight Pericardial complications Akula 2020 2.40 (0.12, 46.84) 5 85 Creta 2020 0.03 (0.00, 0.50) 6.43 He 2020 0.70 (0.31, 1.59) 19.61 0.46 (0.02, 9.80) Mondrago Ignacio 2018 5.61 Opel 2019 1.68 (0.40, 7.09) 13.95 Reddy 2020 0.50 (0.02, 10.53) 5 64 0.63 (0.20, 1.98) Subtotal (I-squared = 47.6%, p = 0.089) 57.09 Phrenic nerve injury Creta 2020 0.65 (0.07, 5.85) 8.94 He 2020 25.93 (1.51, 446.88) 6.24 Kowalski 2020 0.08 (0.00, 1.34) 6.14 Opel 2019 0.71 (0.22, 2.26) 16.41 Reddy 2020 7.64 (0.31, 188.66) 5.20 Subtotal (I-squared = 61.6%, p = 0.034) 1.26 (0.24, 6.64) 42.91 Overall (I-squared = 44.6%, p = 0.054) 0.82 (0.36, 1.87) 100.00 NOTE: Weights are from random effects analysis .00189 528 Favor overnight stay Favor SDD

FIGURE 3b Forest plot of the included studies comparing pericardial complications and phrenic nerve injuries between SDD and overnight stay [Color figure can be viewed at wileyonlinelibrary.com]

given a vast diversity in patients demographics, settings, and procedural protocols from included studies.

Yet, this study is imperfectly not without limitations. First, owing to the inclusion of observational studies, residual confounders are inevitable, especially selection bias from pre-defined inclusion criteria of SDD protocol. Nevertheless, our analysis represented the performance of these protocols in the setting of real-world experience, which should exert better practicalities. Second, study heterogeneity was observed. This was expected due to differences in SDD protocols, follow-up duration, use of echocardiography-guided catheter ablation, centers' experience, variations in AF ablation procedures and techniques, periprocedural care, and outcomes definitions. Third, postprocedural echocardiogram protocol was also vastly varying from each study which may result in an underestimated pericardial/intracardiac complication detection. Fourth, satisfactory rates and economic impacts were not analyzed due to insufficiency of the existing data. Fifth, total complications were non-uniformly defined in each study. We hence decided to assess common complications individually, showing the similar trend with the primary outcome. In addition, our sensitivity analysis, performed by omitting one study each time, confirmed no statistical differences, further verifying robustness of our study.

5 | CONCLUSION

Our study encouraged the use of SDD in patients undergoing AF ablation since there are no major differences in complication rates compared with overnight stay. Despite comprehensive analysis of pooled real-world data, further studies, especially RCTs, are needed to confirm the present findings.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT

The data for this systematic review and all potentially eligible studies are publicly available through the Open Science Framework (URL: https://osf.io/uayp5/).

-WILEY

ORCID

Narut Prasitlumkum MD ¹ https://orcid.org/0000-0002-7956-0574 Ronpichai Chokesuwattanaskul MD ¹ https://orcid.org/0000-0002-4463-7447

Jakrin Kewcharoen MD b https://orcid.org/0000-0003-0959-5576 Nithi Tokavanich MD b https://orcid.org/0000-0003-1846-3786 Leenhapong Navaravong MD b https://orcid.org/0000-0001-7087-1707

REFERENCES

- Kneeland PP, Fang MC. Trends in catheter ablation for atrial fibrillation in the United States. J Hosp Med. 2009;4:E1-5.
- Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation versus antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261-1274.
- 3. Wokhlu A, Monahan KH, Hodge DO, et al. Long-term quality of life after ablation of atrial fibrillation the impact of recurrence, symptom relief, and placebo effect. *J Am Coll Cardiol*. 2010;55:2308-2316.
- Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018;378:417-427.
- Freeman JV, Wang Y, Akar J, Desai N, Krumholz H. National trends in atrial fibrillation hospitalization, readmission, and mortality for medicare beneficiaries. *Circulation*. 2017;135:1227-1239.
- Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. *Int J Stroke*. 2021;16:217-221.
- Writing C, Rao SV, Vidovich MI, et al. ACC expert consensus decision pathway on same-day discharge after percutaneous coronary intervention: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77:811-825.
- Bartsch SM, Ferguson MC, McKinnell JA, et al. The potential health care costs and resource use associated with COVID-19 in the United States. *Health Aff (Millwood)*. 2020;39:927-935.
- 9. Theodoreson MD, Chohan BC, McAloon CJ, et al. Same-day cardiac catheter ablation is safe and cost-effective: experience from a UK tertiary center. *Heart Rhythm*. 2015;12:1756-1761.
- Haegeli LM, Duru F, Lockwood EE, et al. Feasibility and safety of outpatient radiofrequency catheter ablation procedures for atrial fibrillation. *Postgrad Med J.* 1017;86:395-398.
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.
- 12. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for systematic reviews. *Syst Rev.* 2016;5:210.
- 13. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* 2010;25:603-605.
- Spragg DD, Dalal D, Cheema A, et al. Complications of catheter ablation for atrial fibrillation: incidence and predictors. J Cardiovasc Electrophysiol. 2008;19:627-631.
- Steinbeck G, Sinner MF, Lutz M, Muller-Nurasyid M, Kaab S, Reinecke H. Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. *Eur Heart J.* 2018;39:4020-4029.
- 16. Yang E, Ipek EG, Balouch M, et al. Factors impacting complication rates for catheter ablation of atrial fibrillation from. *Europace*;19:241-249.
- Szegedi N, Szeplaki G, Herczeg S, et al. Repeat procedure is a new independent predictor of complications of atrial fibrillation ablation. *Europace*. 2019;21:732-737.

- Padala SK, Gunda S, Sharma PS, Kang L, Koneru JN, Ellenbogen KA. Risk model for predicting complications in patients undergoing atrial fibrillation ablation. *Heart Rhythm*. 2017;14:1336-1343.
- Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. *Psychol Bull*. 1995;117:167-178.
- 20. Chinn S. A simple method for converting an odds ratio to effect size for use in meta-analysis. *Stat Med*. 2000;19:3127-3131.
- 21. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986;7:177-188.
- Creta A, Ventrella N, Providência R, et al. Same-day discharge following catheter ablation of atrial fibrillation: a safe and cost-effective approach. J Cardiovas Electrophysiol. 2020;31:3097-3103.
- He H, Datla S, Weight N, et al. Safety and cost-effectiveness of sameday complex left atrial ablation. *Int J Cardiol.* 2020;322:170-174.
- Reddy SA, Nethercott SL, Chattopadhyay R, Heck PM, Virdee MS Safety, feasibility and economic impact of same-day discharge following atrial fibrillation ablation. *Heart Lung Circ.* 2020;29:1766-1772.
- Bartoletti S, Mann M, Gupta A, et al. Same-day discharge in selected patients undergoing atrial fibrillation ablation. *Pacing Clin Electrophys*iol 2019;42:1448-1455.
- Deyell MW, Leather RA, Macle L, et al. Efficacy and safety of sameday discharge for atrial fibrillation ablation. JACC: Clin Electrophysiol. 2020;6:609-619.
- 27. Kowalski M, Parikh V, Salcido JR, et al. Same-day discharge after cryoballoon ablation of atrial fibrillation: a multicenter experience. *J Cardiovasc Electrophysiol*. 2020;32:183-190.
- Opel A, Mansell J, Butler A, et al. Comparison of a high throughput day case atrial fibrillation ablation service in a local hospital with standard regional tertiary cardiac centre care. *Europace*. 2019;21:440-444.
- Rajendra A, Hunter TD, Morales G, Osorio J. Prospective implementation of a same-day discharge protocol for catheter ablation of paroxysmal atrial fibrillation. J Interventional Cardiac Electrophysiol. 2020:1-7. https://doi.org/10.1007/s10840-020-00914-8 [Epub ahead of print].
- Akula DA, Mariam W, Luthra P, et al. Safety of same day discharge after atrial fibrillation ablation. J Atr Fibrillation. 2020;12:2150.
- Ignacio M, Jarma JJ, Nicolas V, et al. Current safety of pulmonary vein isolation in paroxysmal atrial fibrillation: first experience of same day discharge. J Atr Fibrillation. 2018;11:2077.
- Calkins H, Hindricks G, Cappato R, et al. HRS/EHRA/ECAS/APHRS/ SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *Heart Rhythm*. 2017;14:e445.
- Deshmukh A, Patel NJ, Pant S, et al. In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93 801 procedures. *Circulation*. 2013;128:2104-2112.
- Gupta A, Perera T, Ganesan A, et al. Complications of catheter ablation of atrial fibrillation: a systematic review. *Circ Arrhythm Electrophysiol*. 2013;6:1082-1088.
- Kece F, Zeppenfeld K, Trines SA. The impact of advances in atrial fibrillation ablation devices on the incidence and prevention of complications. Arrhythm Electrophysiol Rev. 2018;7:169-180.
- Tripathi B, Arora S, Kumar V, et al. Temporal trends of in-hospital complications associated with catheter ablation of atrial fibrillation in the United States: an update from Nationwide Inpatient Sample database (2011-2014). J Cardiovasc Electrophysiol. 2018;29:715-724.
- Goya M, Frame D, Gache L, et al. The use of intracardiac echocardiography catheters in endocardial ablation of cardiac arrhythmia: metaanalysis of efficiency, effectiveness, and safety outcomes. J Cardiovasc Electrophysiol. 2020;31:664-673.
- Erden I, Erden EC, Golcuk E, et al. Impact of transesophageal echocardiography during transseptal puncture on atrial fibrillation ablation. J Arrhythm. 2016;32:170-175.

Kaiser DW, Fan J, Schmitt S, et al. Gender differences in clinical outcomes after catheter ablation of atrial fibrillation. JACC Clin Electrophysiol. 2016;2:703-710.

II FY

- 40. Kuck KH, Brugada J, Furnkranz A, et al. Impact of female sex on clinical outcomes in the FIRE AND ICE trial of catheter ablation for atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2018;11:e006204.
- Dugo D, Bordignon S, Perrotta L, Furnkranz A, Schmidt B. Catheter ablation of atrial fibrillation in females. J Atr Fibrillation. 2013;6: 893.
- Salton CJ, Chuang ML, O'Donnell CJ, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the framingham heart study offspring cohort. J Am Coll Cardiol. 2002;39: 1055-1060.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Prasitlumkum N, Cheungpasitporn W, Chokesuwattanaskul R, et al. Comparison between same-day discharge and overnight stay after atrial fibrillation ablation: systematic review and meta-analysis. *Pacing Clin Electrophysiol*. 2021;44:2054–2066. https://doi.org/10.1111/pace.14380